Latest Industry Insights

Researchers have developed a mathematical model that may offer an alternative to relying on ultrasound information for calculating gestational age. The model, utilizing a "metabolomic fingerprint" approach, may overcome barriers in preterm death research.

The Rare Genomics Institute announced on Rare Disease Day 2019 that they had used the Mastermind Genomic Search Engine, a clinical decision support tool by Genomenon, to diagnose a rare disease patient. We spoke to Mark Kiel, MD, PhD, Founder and Chief Science Officer at Genomenon and Romina Ortiz, COO at the Rare Genomics Institute, to learn more about the application of this technology in rare diseases.

Our recent social media poll on "book recommendations for scientists" provided an incredible response. We decided to collate this information and give you the perfect excuse to treat yourself to a new read. Enjoy!

The thought that compounds in the breath could be measured and assessed to diagnose different aspects of pathology is an exciting prospect. To learn more about the breathalyzer platform being used in clinical trials to detect early cancer biomarkers, we spoke to Chris Claxton, head of investor relations at Owlstone Medical.

The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.

Recently, the FDA granted de novo classification for eight fluorescence in situ hybridisation (FISH) probes for myelodysplastic syndromes and acute myeloid leukaemia. We spoke with Steve Chatters, Director of Medical Affairs at Oxford Gene Technology, to learn more about the application of FISH probes in modern medicine.

We caught up with Abcam's Head of Custom Services, Jamie Campbell, who recently presented at the Protein & Antibody Engineering Summit, Europe. Jamie discusses the company’s approach to discovering antibodies – key reagents in drug discovery, in vitro diagnostics and therapeutics.

We spoke to Dr Jack Regan, CEO of LexaGene, a biotechnology company developing a fully automated pathogen detection platform, and inventor of their patented microfluidic system, about the foundations and evolution of the system, and the future outlook for the tool.

We recently spoke to Alif Saleh, CEO of Scipher Medicine to learn how RNA data from a patient’s blood sample can be used to determine the underlying molecular processes driving a disease, and establish how well a patient will respond to a particular therapy.

How can meat processors and retailers assure their customers that the meat they are buying is what is declared on the packaging? A genetic fingerprinting system is now on hand to provide definitive, traceable evidence.